SonoVascular's Breakthrough: First Human Trial of SonoThrombectomy™ System in Chile

SonoVascular, Inc. has achieved a significant milestone with the successful treatment of the first patient using its innovative SonoThrombectomy™ system as part of a pioneering study conducted at DIPRECA Hospital in Santiago, Chile. This unique system, overseen by experts Dr. Manuel Espíndola and Dr. Albrecht Krämer, integrates microbubble-mediated cavitation with precise low-dose thrombolytic delivery, offering an effective and safe treatment for venous thromboembolism (VTE) without the blood loss associated with more invasive techniques.

The procedure not only resulted in the rapid elimination of the thrombus but also preserved the integrity of the vascular walls, highlighting the potential of this system to revolutionize VTE treatment. Just 48 hours after the procedure, the patient was discharged, showing a quick and complication-free recovery, thus demonstrating the efficacy and safety of the SonoThrombectomy™ system.

Based in Chapel Hill, NC, SonoVascular continues to lead in the development of innovative therapeutic medical devices. To learn more about how this technology is changing the treatment of vascular diseases, we invite you to click the button below and read the full article on PR Newswire.

About SonoVascular, Inc.

SonoVascular designs and develops innovative therapeutic ultrasound-based medical devices for treating vascular disease. Founded in 2018, SonoVascular developed the SonoThrombectomy System, a novel pharmaco-mechanical ultrasound facilitated thrombectomy system for VTE that utilizes microbubble-mediated cavitation as a core enabling mechanism of action to more effectively remove VTE blood clots. The SonoThrombectomy System has been engineered to address and overcome the deficiencies and limitations of current interventional devices. It is a catheterization laboratory-based solution that has been designed to maximize the reduction in clot burden, reduce the dose and duration as well as enhance the delivery of thrombolytics to levels that optimize safety and effectiveness, and eliminate the need for patients to be treated in the ICU. SonoVascular is headquartered in Chapel Hill, NC.

For more information, visit www.sonovascular.com.